EP Patent

EP0344603A1 — Pharmaceutical composition of dihydropyridine compound

Assigned to Zeria Pharmaceutical Co Ltd · Expires 1989-12-06 · 36y expired

What this patent protects

A parmaceutical composition comprising: a 1:1 solvate of 5-(5,5-dimethyl-1,3,2-dioxaphosphorinane-2-yl)-1,4-­dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3-pyridine carboxylic acid 2-(phenyl(phenylmethyl)amino) ethyl ester P-oxide hydrochloride-ethanol (NZ-105) and hydroxypropyl­methyl…

USPTO Abstract

A parmaceutical composition comprising: a 1:1 solvate of 5-(5,5-dimethyl-1,3,2-dioxaphosphorinane-2-yl)-1,4-­dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3-pyridine carboxylic acid 2-(phenyl(phenylmethyl)amino) ethyl ester P-oxide hydrochloride-ethanol (NZ-105) and hydroxypropyl­methylcellulose acetate succinate is disclosed. The composition can easily be prepared into tablets, capsules, granules, and powders, which exhibit an enhanced bioavailability, e.g. provides a high blood concentration of the active component NZ-105 and ensures a high total drug absorption.

Drugs covered by this patent

Patent Metadata

Patent number
EP0344603A1
Jurisdiction
EP
Classification
—
Expires
1989-12-06
Drug substance claim
No
Drug product claim
No
Assignee
Zeria Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.